The Securities and Exchange Commission (SEC) investigation commenced in March 2004 and NeoPharm believes it concerned disclosures regarding the development of two drug candidates.
The decision of the SEC to terminate its investigation is not a finding or judgment regarding the matters investigated.
NeoPharm is a publicly traded biopharmaceutical company dedicated to the research, development and commercialization of new cancer drugs for therapeutic applications. NeoPharm has built its drug portfolio based on its two novel proprietary technology platforms: a tumor-targeting platform and the NeoLipid drug delivery system.